C-peptide's effect on low blood sugar response
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests whether C-peptide (a substance made by the pancreas) can help your body respond better to low blood sugar (hypoglycemia). It's a very early trial for people without certain health conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your body mass index (BMI) must be under 30.
- You cannot be pregnant or breastfeeding.
- You must not smoke cigarettes.
- You cannot have HIV or hepatitis.
- You must not have heart or blood vessel disease.
- You must not have microvascular disease (like eye, nerve, or kidney damage from diabetes).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called CNP-103 for people ages 12-35 who were recently diagnosed (within 6 months) with stage 3 type 1 diabetes. The goal is to see if the drug can help preserve the body's ability to make some insulin, potentially slowing the need for more insulin shots.
This study is looking for adults with type 1 diabetes to help improve guidelines for preventing and treating low blood sugar (hypoglycemia). The goal is to make recommendations that are more practical and safer for people like you.
This trial tests a new treatment made from pig pancreatic cells (called OPF-310) that are placed under the skin to help control blood sugar in people with type 1 diabetes. It is for those whose diabetes is difficult to manage and who have dangerous low blood sugar episodes.
This early study tests how people respond to different degrees of low blood sugar. It may help researchers understand what “low sugar” feels like and how to make it safer to detect and manage.
This Phase 1/2 study tests whether CELZ-201 is safe and can help the body keep making some of its own insulin in people who were recently diagnosed with type 1 diabetes. You may be eligible if your diabetes started within the past year and your tests show you still have some insulin-making activity.
This study tests a new treatment called E-islet 01, which may help people with type 1 diabetes who have very low natural insulin production and have had dangerous low blood sugar events. The goal is to see if it is safe and can reduce those episodes.
Hear when a new Hypoglycemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.